CRANBURY, N.J. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 2, 2020 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2019 .
CRANBURY, N.J. , Feb. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient centric biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that one oral presentation and nine posters highlighting its
2020 Galafold Revenue Guidance of $250M-$260M Focused on Pompe Phase 3 PROPEL study and manufacturing to support 2021 BLA and MAA Continued Progress Across Industry Leading Rare Disease Gene Therapy Portfolio Strong Balance Sheet with $450M+ Cash – Cash Runway Well into 2022 CRANBURY, N.J. , Jan.
Galafold Revenue of $181 Million for Full-Year 2019 and $54 Million in Q4 Reflects Continued Strong Adoption & Patient Adherence in All Key Global Regions Galafold Marketing Authorizations Recently Received in Brazil , Colombia and Taiwan Galafold on Track for $500M Revenue by 2023 with Potential
123 Patients Enrolled in Phase 3 PROPEL Study – Enrollment Completed in 4Q2019 Company Plans to Apply for and Initiate a Rolling Biologics License Application (BLA) for AT-GAA in 2020 with Addition of Full Clinical Results in 1H2021 to Support Full Approval under Fast Track Designation Promising
3Q19 Galafold ® (migalastat) Revenue of $48 .8M and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Reiterating Upwardly Revised FY19 Revenue Guidance of $170M-$180M Complete Enrollment of 120+ Patients in AT-GAA Pompe Pivotal Study on Track by YE19 Continued
CRANBURY, N.J. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 11, 2019 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2019 .
New Data Support Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years Post-Treatment CRANBURY, N.J. , and CHARLOTTE, N.C. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics
Analyst Day 2019 to Highlight Financial Outlook and Robust Portfolio of Novel Therapies for Rare Metabolic Diseases 3Q19 Galafold ® (migalastat) Preliminary Unaudited Revenue of ~$48M+ and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Company Raises Lower End of FY19 Global
Persistent and Durable Responses Across Safety, Functional Outcomes and Biomarkers for ERT-Naïve and ERT-Switch Patients in Cohorts 1, 2 and 3 Out to Month 24 Data in Additional Switch Patients (Cohort 4) Consistent with Reponses in Previous Cohorts Demonstrating Improvements in Multiple Measures